PTAB denies post-grant review of two Compass Pathways patents

COMPASS Pathways plc

Patent Trial & Appeal Board denied institution of post-grant review for US patents 10,947,257 and 10,954,259 on June 22, 2022.
Freedom to Operate had filed petitions challenging patentability on three grounds: improper subject matter, obviousness, and lack of enablement.
Decision upholds validity of key patents covering COMPASS's psilocybin-related intellectual property.
Outcome removes near-term patent invalidation risk for Compass Pathways.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.